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Abstract
Background: Patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis, with a median overall
survival (OS) of ~7 months. Methotrexate is sometimes used following platinum failure or in patients not fit enough
for platinum therapy, but this agent has not demonstrated any OS improvement. Targeted therapies are a novel
approach, with the EGFR-targeting monoclonal antibody cetuximab (plus platinum-based chemotherapy) approved
in the US and Europe in the first-line R/M setting, and as monotherapy following platinum failure in the US. However,
there is still a high unmet medical need for new treatments that improve outcomes in the second-line R/M setting
following failure on first-line platinum-containing regimens. Afatinib, an irreversible ErbB family blocker, was recently
approved for the first-line treatment of EGFR mutation-positive metastatic non-small cell lung cancer. Afatinib has
also shown clinical activity similar to cetuximab in a Phase II proof-of-concept HNSCC trial. Based on these observations,
the Phase III, LUX-Head & Neck 1 study is evaluating afatinib versus methotrexate in R/M HNSCC patients following
progression on platinum-based chemotherapy in the R/M setting.
Methods/Design: Patients with progressive disease after one first-line platinum-based chemotherapy are randomised
2:1 to oral afatinib (starting dose 40 mg once daily) or IV methotrexate (starting dose 40 mg/m
2 once weekly)
administered as monotherapy with best supportive care until progression or intolerable adverse events. Efficacy of
afatinib versus methotrexate will be assessed in terms of progression-free survival (primary endpoint). Disease progression
will be evaluated according to RECIST v1.1 by investigator and independent central review. Secondary endpoints include
OS, tumour response and safety. Health-related quality of life and biomarker assessments will also be performed.
Discussion: If the LUX-Head & Neck 1 trial meets its primary endpoint, it will demonstrate the ability of afatinib to elicit
an improved treatment benefit versus a commonly used chemotherapy agent in the second-line treatment of R/M
HNSCC patients who have failed on first-line platinum-based therapy, confirm the clinical efficacy of afatinib observed in
the Phase II proof-of-concept study, and establish a new standard of care for this patient population.
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Head and neck squamous cell carcinoma (HNSCC) has
an incidence of more than 600,000 new cases worldwide
per year [1]. The majority of HNSCC patients are diag-
nosed in the later stages of the disease, with more
than half of patients having locoregionally advanced (LA)
HNSCC at the time of diagnosis and approximately 10%
of patients having metastatic disease [2]. Prognosis in LA
patients is poor, with around 50% of unresectable pa-
tients relapsing 5 years after receiving definitive chemo-
radiotherapy (CRT) [3,4], a standard treatment in this
setting. Resectable patients receiving adjuvant CRT fol-
lowing surgery have a 5-year recurrence rate of 20% [5].
Furthermore, recurrent and/or metastatic (R/M) HNSCC
patients receiving first-line chemotherapy only have a
median overall survival (OS) of approximately 7 months
[6]. Therefore, the R/M setting represents a group of pa-
tients who require novel treatment approaches.
Non-targeted treatments for R/M HNSCC
The most common non-targeted treatment approach in
R/M HNSCC is a platinum-containing agent combined
with either a taxane or 5-fluorouracil (5-FU) [7]. Response
rates and OS in R/M HNSCC following platinum-based
doublet chemotherapy in the first-line setting are low. Re-
sults from four large randomised studies in this setting
comparing cisplatin plus 5-FU with other single-agent
chemotherapy agents demonstrated that combination
regimens elicited response rates of around 20–30% [8-11].
In three further studies assessing cisplatin in combination
with paclitaxel, median OS was reported to be between 6.5
and 8.0 months [12-14]. Moreover, following failure on a
platinum-containing regimen there is no defined standard
of care and second-line treatment options for R/M patients
are limited, thus highlighting the need for alternative treat-
ments that can improve outcomes in these patients.
Methotrexate is commonly used in R/M HNSCC [7]
and continues to be used as a standard comparator in
some Phase III trials, mainly after platinum failure or in
patients judged unfit for platinum therapy [9,15-17].
Taxanes have also been used in this setting. However,
no study has been able to show that these agents im-
p r o v eO S .T h ea b i l i t yo fm e t h o t r e x a t et oi n c r e a s eO S
in HNSCC patients has not been formerly demon-
strated in Phase III trials. This agent produces a re-
sponse of short duration (approximately 3–6 months) in
around 4–24% of cases and only rarely elicits complete
responses (CRs) [15,16,18-20].
Targeted treatment approaches
A recent approach to new cancer therapies has been to
develop targeted agents that inhibit particular signalling
pathways implicated in tumourigenesis. Epidermal growth
factor receptor (EGFR; ErbB1) is a member of the ErbB
family of receptor tyrosine kinases that plays an integral
role in the oncogenesis of several ErbB-driven cancers, in-
cluding HNSCC [21]. Overexpression of EGFR provides
tumour cells with growth and survival advantages, and this
process is thought to substantially contribute to the aggres-
sive nature of cancer cell proliferation. Approximately 90%
of patients with HNSCC overexpress EGFR and prognosis
for these patients can be lower than for patients without
high levels of EGFR expression, with increased EGFR ex-
pression correlating with a reduction in recurrence-free
survival or OS rates [21]. One study has shown that in pa-
tients with laryngeal squamous cell carcinoma, those with
low EGFR expression levels have a 5-year OS rate of 81%
compared with 25% for patients with high levels of EGFR
expression [22].
Cetuximab is an EGFR-targeting monoclonal antibody
and is the only targeted treatment approved in the US
and Europe for the treatment of HNSCC in combination
with radiotherapy for LA disease and in combination with
platinum-based chemotherapy for R/M disease [23,24]. It
is also approved in the US as monotherapy in R/M
HNSCC following progression on platinum-based chemo-
therapy [23]. In a Phase III trial in R/M patients, combin-
ation treatment with cetuximab and cisplatin led to an
objective response rate (ORR) of 26% versus 10% with cis-
platin plus placebo (p=0.03) [25]. However, owing to this
trial being underpowered, no significant difference was ob-
served for progression-free survival (PFS) or OS in both
arms. In the larger confirmatory EXTREME study, cetuxi-
mab in combination with platinum-based chemotherapy
elicited an OS benefit in untreated R/M HNSCC patients
versus chemotherapy alone [6]. The median OS was pro-
longed from 7.4 months in patients receiving chemo-
therapy alone to 10.1 months in the cetuximab plus
chemotherapy arm. Median PFS was also increased from
3.3 months in the chemotherapy alone group to 5.6 months
in the combination group.
In platinum-refractory R/M HNSCC patients with dis-
ease progression, three studies have been performed
assessing the efficacy of cetuximab either alone or in
combination with platinum-based chemotherapy. In 2005,
two trials evaluated cetuximab in combination with either
cisplatin or carboplatin in this setting. Herbst et al. re-
ported an ORR of 10% and OS of 5.2 months in patients
receiving cetuximab plus cisplatin [26] and similar results
were observed by Baselga et al. who determined an ORR
of 10% and OS of 6 months following treatment with
cetuximab plus cisplatin or carboplatin [27]. Cetuximab
has also been investigated as a monotherapy in the R/M
population in patients who have failed platinum-based
chemotherapy, with a best overall response rate of 13%
and OS of 5.9 months observed [28]. This trial suggests
that single-agent cetuximab offers similar efficacy to com-
bination treatment with platinum-based chemotherapy in
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therapy. A pooled analysis of these three trials was per-
formed in 2008, which compared them to a retrospective
trial by Leon et al. [29]. Leon et al. assessed the outcomes
of platinum-refractory R/M HNSCC patients treated be-
tween 1990 and 2000 with best supportive care or various
second-line therapies. This indirect comparison indicated
that median OS may be increased by approximately
2 months when cetuximab is administered following plat-
inum failure, with OS ranging between 5.2 and 6.1 months
in the cetuximab studies versus 3.4 and 3.6 months in Leon
et al.’s retrospective analysis [30].
Several other targeted agents are currently being inves-
tigated for HNSCC, including the monoclonal antibody
panitumumab, the small-molecule tyrosine kinase in-
hibitors dacomitinib and lapatinib, and the oncolytic
virus reolysin. The monoclonal antibody nimotuzumab is
already approved in numerous countries, including Brazil,
India, China, Argentina and Indonesia. However, this is still
under investigation for HNSCC in the US and Europe.
Acquired or primary resistance to targeted therapies is
common, with several mechanisms being implicated in
this process. These postulated or hypothetical mecha-
nisms include receptor-independent activation of down-
stream signalling cascades, cross-talk with other receptor
tyrosine kinases, and environmental factors, such as viral
infections and inflammatory agents [31]. A novel approach
to overcome treatment resistance is inhibition of multiple
ErbB family members simultaneously or binding multiple
ErbB family members irreversibly [32]. By blocking
all ErbB family members, greater efficacy may be achieved
as all ErbB-driven oncogenic pathways are compromised.
Furthermore, irreversible inhibition, mediated by covalent
binding to specific residues of the target, may lead to sus-
tained suppression of tumour growth as prolonged cellular
activity is inhibited.
Afatinib, an irreversible ErbB family blocker
Afatinib is an oral ErbB family blocker that completely
and irreversibly blocks signalling by all relevant ErbB
family members, including EGFR, human epidermal
growth factor receptor-2 (ErbB2) and ErbB4, and also
blocks transphosphorylation of ErbB3 [33,34]. It is ap-
proved in the US for the first-line treatment of EGFR
mutation-positive metastatic NSCLC and it is also being
developed for the treatment of a number of other ErbB-
driven tumours, including breast cancer and HNSCC.
In the LUX-Lung clinical trial programme, afatinib has
been investigated for the treatment of EGFR mutation-
positive NSCLC either in the first-line setting [35-37] or in
patients with no more than one prior chemotherapy [38].
It has also been assessed following chemotherapy and/or
EGFR tyrosine kinase inhibitor therapy [39-43]. In the
proof-of-concept LUX-Lung 2 trial, afatinib monotherapy
elicited an ORR of 61% in NSCLC patients [38] and in
LUX-Lung 3, to our knowledge being the largest, prospect-
ive, randomised trial in EGFR mutation-positive NSCLC
patients, the primary endpoint of PFS was met, with a me-
dian PFS of 11.1 months observed for afatinib-treated pa-
tients versus 6.9 months in chemotherapy-treated patients
[35]. Afatinib has also demonstrated a manageable safety
profile, with recent pooled data analyses in patients with
solid tumours showing that gastrointestinal and dermato-
logical adverse events in particular can be effectively man-
aged in this patient population [44,45].
In HNSCC, afatinib has demonstrated preclinical ac-
tivity in both in vitro and in vivo models [46,47] and
clinical activity in a proof-of-concept Phase II study
[48,49]. In the human HNSCC FaDu cell line, afatinib
inhibited tumour cell proliferation in the low nanomolar
concentration range, with additive growth inhibitory ef-
fects demonstrated when combined with standard che-
motherapies versus single-agent treatment [47]. The
Phase II proof-of-concept study showed comparable activ-
ity between afatinib and cetuximab in R/M HNSCC pa-
tients following failure of platinum-based chemotherapy.
In Stage I, ORRs were 8.1% in afatinib-treated patients
and 9.7% in cetuximab-treated patients (independent cen-
tral review) [48]. Furthermore, in Stage II of the study,
after crossover to the opposite treatment arm, afatinib
elicited a disease control rate of 33% in patients who re-
ceived cetuximab in Stage I (vs. 19% in cetuximab-treated
patients after crossover from afatinib) and demonstrated
PFS of 9.3 weeks in the afatinib group versus 5.7 weeks in
the cetuximab group, suggesting sequential therapy with
afatinib may be efficacious in patients pretreated with an
EGFR-targeted therapy [49]. Therefore, these data warrant
further investigation of this compound for the treatment
of R/M HNSCC.
In afatinib monotherapy trials, the maximum tolerated
dose was determined to be continuous daily afatinib at
either 40 mg or 50 mg [50,51]. Afatinib 50 mg/day was
the starting dose used in the proof-of-concept LUX-
Lung 2 trial in EGFR mutation-positive patients who
had received no more than one previous chemotherapy
[38]. However, the dose was reduced to 40 mg/day to
improve the safety profile of afatinib and, as there was
no difference in efficacy in patients receiving both doses,
40 mg/day afatinib was the starting dose used in the sub-
sequent LUX-Lung 3 and 6 trials [35,36]. In the HNSCC
proof-of-concept trial, a starting dose of 50 mg/day afati-
nib was used [48]; however, afatinib demonstrated a more
manageable safety profile at 40 mg/day in this study and
so this is the chosen starting dose of afatinib in LUX-
Head & Neck 1, with individual dosing allowed depend-
ing on how well patients tolerate treatment. It has been
established that using a dose-reduction scheme in the
administration of afatinib is an effective approach to
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continuation of afatinib. Therefore, this is the approach
being adopted in LUX-Head & Neck 1.
The LUX-Head & Neck 1 study (NCT01345682) has
been initiated to assess the efficacy and safety of afatinib
versus methotrexate in the second-line treatment of
R/M HNSCC patients following failure of first-line
platinum-based chemotherapy. Given methotrexate is
a standard treatment in R/M HNSCC in many countries,
and is used as a standard comparator in other Phase III
trials, this agent is considered an appropriate comparator
in this study. In particular, this second-line trial is pow-
ered to detect superiority of afatinib over methotrexate
in terms of a PFS and OS benefit. There are currently
no approved predictive tumour- or serum-derived bio-
markers guiding treatment with ErbB-directed therapies
in HNSCC. Therefore, this study also includes a biomarker
assessment part.
Methods/Design
Objectives
The primary objective of LUX-Head & Neck 1 is to evalu-
ate the superiority of afatinib to methotrexate in terms of
PFS in patients with R/M HNSCC who have progressed
after platinum-based therapy for R/M disease. Progression-
free survival has been chosen as the primary endpoint
of this study because further treatments following dis-
ease progression potentially dilute the effect on sur-
vival afforded by the treatments under investigation.
Secondary objectives include OS, ORR, health-related
quality of life (HRQoL) and safety of afatinib versus
methotrexate in this patient population.
Study design and treatments
In this Phase III, open-label, multicentre, randomised
trial, eligible patients will be randomised 2:1 to con-
tinuous, once-daily afatinib or weekly methotrexate,
administered as monotherapy with best supportive care.
Randomisation will be stratified based on Eastern Co-
operative Oncology Group (ECOG) performance score
(0 vs. 1) and prior use of EGFR-targeted antibody therapy
in the R/M setting. Randomised patients will be treated
until progression, unacceptable adverse events (AEs) or
other reasons necessitating treatment withdrawal (Figure 1).
Patients may continue study medication beyond disease
progression in case of clinical benefit, as long as this is
judged beneficial by the investigator.
Individualised dosing will be adopted based on toler-
ability, with the afatinib starting dose being 40 mg once
daily, increasing to 50 mg following minimal drug-
related AEs after at least 4 weeks of treatment. The afati-
nib dose will be reduced in decrements of 10 mg to a
minimum of 20 mg in the event of specific drug-related
AEs. Methotrexate will be administered as intravenous
bolus injections of 40 mg/m
2 once a week, with the op-
tion to increase the dose to 50 mg/m
2 in the event of no
or minimal drug-related AEs after at least 2 weeks of
treatment. The methotrexate dose will be reduced in dec-
rements of 10 mg/m
2 to a minimum of 20 mg/m
2 in the
event of drug-related AEs.
LUX-Head & Neck 1 is being conducted worldwide
and target accrual is 474 patients. The trial is being car-
ried out in compliance with the protocol, the principles
laid down in the Declaration of Helsinki, in accordance
with the International Conference on Harmonization
Guideline for Good Clinical Practice (ICH-GCP) and in
accordance with applicable regional-specific regulatory
requirements. The study protocol has been reviewed by
Independent Ethics Committees in each country, accord-
ing to national and international regulations, and written
informed consent will be obtained from each patient be-
fore any study-specific screening assessments are per-
formed, according to ICH-GCP and regulatory and legal
requirements of the participating country. The Inde-
pendent Ethics Committees that reviewed the study
protocol are as follows: Argentina (Comité de Etica de
Investigacion Instituto de Oncología Angel Roffo; Cte de
Docencia e Investigación de ISIS; Comité Independiente
de Etica para Ensayos en Farmacología Clinica; Comité
de Docencia e Investigación de CETEN; Comité de Etica
del CER Investigaciones Clinicas); Austria (Ethics Com-
mittee of the Medical University of Vienna); Belgium
(Commissie Medische Ethiek – UZ Leuven); Brazil
(Comitê de Ética em Pesquisa da Faculdade de Medicina
da Universidade de São Paulo; Comitê de Ética em
Pesquisa em Seres Humanos do Hospital Pró-Cardíaco
Pronto Socorro Cardiológico; Comitê de Ética em Pesquisa
em Seres Humanos da Irmandade da Santa Casa de
Misericórdia de Porto Alegre; Comitê de Ética em Pesquisa
em Seres Humanos da Fundação Pio XII - Hospital do
Câncer de Barretos; Comitê de Ética em Pesquisa em Seres
Humanos da Fundação Hospital Amaral Carvalho; Comitê
de Ética em Pesquisa em Seres Humanos da Fundação
Antônio Prudente - Hospital do Câncer - AC Camargo;
Comitê de Ética em Pesquisa em Seres Humanos da
Universidade de Passo Fundo); Czech Republic (Ethics
Committee of Fakultní nemocnice Olomouc a Lékařské
fakulty UP v Olomouci; Ethics Committee of Teaching
Hospital Bulovka; Ethics Committee of General Teaching
Hospital Prague); Denmark (De Videnskabsetiske Komiteer
for Region Hovedstaden); France (Comité de Protec-
tion des Personnes Sud-Est IV, Centre Léon Bérard);
Germany (Ethik-Kommission der Medizinischen Fakultät
der Universität Duisburg-Essen; Ethik-Kommission des
Landes Berlin – Landesamt für Gesundheit und Soziales;
E t h i k - K o m m i s s i o na nd e rM e d i z i n i s c h e nF a k u l t ä td e r
RWTH Aachen; Ethik-Kommission an der Medizinischen
Fakultät der Universität Leipzig; Ethikkommission der
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nischen Hochschule Hannover; Medizinische Ethik-
kommission II der Medizinischen Fakultät Mannheim;
Geschäftsstelle der Ethik-Kommission; Ethikkommission
an der Technischen Universität Dresden); Greece (National
Ethics Committee); Israel (Helsinki Committee); Italy
(Comitato Etico Interaziendale dell’asl s. croce e carle di
Cuneo; Comitato Etico Regionale della Liguria; Comitato
Etico dell’IRCCS Istituto Nazionale per lo Studio e la
Cura dei Tumori Fondazione Giovanni Pascale di Napoli;
Comitato Etico Interaziendale della Provincia di Messina;
Comitato Etico Palermo; Comitato Etico per la Speri-
mentazione Clinica della Provincia di Venezia e IRCCS
San Camillo; Comitato Etico Centrale IRCCS Lombardia –
C/o Fondazione IRCCS Istituto Nazionale dei Tumori;
Comitato Etico dell’AOU di Cagliari; Comitato Etico della
Ausl della Valle d’Aosta; Comitato Etico Lazio 1 - Azienda
Ospedaliera S. Camillo-Forlanini); Japan (IRB of Jichi
Medical University Hospital; The IRB of National Can-
cer Center Hospital East; IRB of National Hospital
Organization Tokyo Medical Center; IRB of Shizuoka
Cancer Center; IRB of Aichi Cancer Center Hospital;
IRB of Kobe University Hospital; IRB of National Hos-
pital Organization Shikoku Cancer Center; IRB of Tokai
University Hospital; IRB of Osaka Medical Center for
Cancer and Cardiovascular Diseases; IRB of Hyogo
Cancer Center; IRB of The Jikei University Hospital of
Medicine; IRB of Japanese Foundation for Cancer Re-
search; IRB of Miyagi Cancer Center); Mexico (Instituto
Nacional de Cancerología – Comité de Bioética; Instituto
Nacional de Cancerología – Comité Científico); Russia
(Ethics Committee within Clinical Oncology Center; Ethics
Committee within Bashkir State Medical University; Ethics
Committee within Kursk Regional Clinical Oncological
Center; Ethics Committee within St. Petersburg Pavlov
State Medical University; Local Ethics Committee within
Blokhin Cancer Research Center; Ethics Committee within
Pyatigorsk Oncology Center); South Africa (Human Re-
search Ethics Committee; Faculty of Health Sciences Re-
search Ethics Committee – University of Pretoria and
Pretoria Academic Hospitals; Pharma Ethics); Spain (CEIC
Hospital Universitari de la Vall d’Hebrón; CEIC Área de
Salud de Salamanca; Comité Etico de Investigación Clínica
d eA r a g ó n ;C E I CH o s p i t a lC l í n i ciP r o v i n c i a ld eB a r c e l o n a ,
Agencia de Ensayos Clínicos – Servicio de Farmacia; CEIC
Hospital de Girona “Dr. Josep Trueta”;C E I CA u t o n ó m i c o
de Ensayos Clinicos de Andalucía); Sweden (Regionala etik-
prövningsnämnden); Switzerland (Ethikkommission beider
Basel, EKBB; Kantonale Ethikkommission Bern KEK); USA
(University of Arkansas for Medical Sciences Institutional
Review Board; Thomas Jefferson University Office of
Human Research Institutional Review Board; Fox Chase
Cancer Center Institutional Review Board; Committee on
Research Involving Human Subjects; Schulman Associates
IRB; Institutional Review Board, Methodist Hospital,
Omaha; UT Health Science Center Institutional Review
Board; Dana-Farber Cancer Institute Institutional Review
Board; University of Texas MD Anderson Cancer Center;
Ingalls Memorial Hospital; Memorial Healthcare System –
Western Institutional Review Board).
Figure 1 Trial design. *Dose escalation to 50 mg once daily and/or reduction to 40, 30, then 20 mg once daily.
†Dose can be escalated to
50 mg/m
2 weekly and/or reduction to 40, 30, then 20 mg/m
2 weekly. HNSCC=head and neck squamous cell carcinoma; CT=chemotherapy;
MTX=methotrexate; PFS=progression-free survival.
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Eligible patients must be at least 18 years of age and
have histologically or cytologically confirmed squamous
cell carcinoma of the oral cavity, oropharynx, hypophar-
ynx or larynx, which has recurred/metastasised and is
not amenable for salvage surgery or radiotherapy. Patients
are required to have documented progressive disease (PD)
based on investigator assessment according to Response
Evaluation Criteria in Solid Tumors (RECIST) following
receipt of at least two cycles of cisplatin or carboplatin ad-
ministered for R/M disease. Patients must have measurable
disease according to RECIST Version 1.1 and an ECOG
performance status of 0 or 1 at the time of randomisation.
Main exclusion criteria include PD within 3 months of
completion of curatively intended treatment of LA or
metastatic HNSCC, primary tumour site of the nasophar-
ynx (of any histology), sinuses and/or salivary glands, any
other than one previous platinum-based systemic regimen
given for R/M disease, prior treatment with EGFR-targeted
small molecules, and pregnancy or breastfeeding.
Efficacy assessments
Progression-free survival, the primary endpoint, is de-
fined as the time from the date of randomisation to the
date of progression or to the date of death, whichever
occurs first. Computed tomography scans or magnetic
resonance imaging will be performed at baseline, every
6 weeks during the first 24 weeks after randomisation,
and every 8 weeks thereafter. Disease progression will
be evaluated according to RECIST Version 1.1 by
independent central review. Overall survival, the key
secondary endpoint, is defined as the time from the date
of randomisation to the date of death (regardless of the
cause of death). Other efficacy endpoints include ORR,
defined as CR or partial response determined by RECIST
Version 1.1, and tumour shrinkage, defined as the
maximum decrease in the sum of the longest diameters
of the target lesions.
Safety assessments
Safety endpoints include the overall incidence and inten-
sity of AEs, e.g. gastrointestinal events (vomiting, nausea,
diarrhoea), skin reactions (rash, acne) and change from
baseline for all laboratory tests. The incidence and inten-
sity of AEs will be graded according to United States
National Cancer Institute Common Terminology Criteria
for Adverse Events Version 3.0.
HRQoL assessment
Health-related quality of life will be assessed using ques-
tionnaires by the European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) and the EORTC Head and Neck
cancer-specific supplementary module (EORTC QLQ-
H&N35). The main analysis of HRQoL questionnaires will
focus on the following scales: Pain scale (composite of
items 31–34 of the EORTC QLQ-H&N35); swallowing
scale (composite of items 35–38 of the EORTC QLQ-
H&N35); global health status/QoL scale (composite of
items 29 and 30 of the EORTC QLQ-C30). Health-related
quality of life data will also be collected using the EQ-5D
questionnaire and will be analysed descriptively.
Biomarker assessment
Participation in the biomarker part of the study is volun-
tary and not a prerequisite for participation in the trial.
A separate informed consent to allow for biomarker ana-
lyses must be given in accordance with local ethical and
regulatory requirements. Pharmacodynamic biomarker
analyses will be based on archival tumour tissue and
serum samples. For serum-derived biomarkers, blood
samples will be taken from consented patients before
the start of treatment (at Visit 2) and an evaluation of
the VeriStrat proteomic signature will be performed. For
tumour tissue-derived biomarkers, archival tumour tis-
sue will be analysed for the presence of p16 by immuno-
histochemistry. Additional exploratory biomarker analyses
are planned, including determination of ErbB ligands, ErbB
receptor expression, EGFR mutation status and EGFR
downstream signalling markers.
Statistical analyses
Outcome analyses
Progression-free survival will be analysed using a stratified
log-rank test with baseline ECOG performance score and
prior use of EGFR-targeted antibodies for R/M HNSCC
being the stratification factors. The Kaplan-Meier method
will be used to summarise PFS times for each treatment
group and the stratified Cox proportional hazards model
will be used to determine the hazard ratio between the two
treatment groups. OS will be analysed, similarly to PFS,
using the stratified logrank test, the Kaplan-Meier method
and the Stratified Cox Proportional Hazards model.
Trial status
The trial was initiated in January 2012 and is currently
recruiting patients in Argentina, Austria, Belgium, Brazil,
Czech Republic, Denmark, France, Germany, Greece,
Israel, Italy, Japan, Mexico, Russia, South Africa, Spain,
Sweden, Switzerland and the USA (Figure 2).
Discussion
A detailed account of the LUX-Head & Neck 1 trial has
been provided here to increase awareness of the study
and provide a detailed rationale for why this study is be-
ing performed. Results are anticipated to demonstrate
improved efficacy of afatinib compared with methotrex-
ate in platinum-failure HNSCC patients and expand
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current unmet medical need of these patients. This is
one of two Phase III studies of afatinib in HNSCC, with
LUX-Head & Neck 2 (NCT01345669) assessing afatinib
in the adjuvant setting in unresected, intermediate-to-
high risk LA HNSCC patients; this trial is also currently
recruiting patients. Afatinib has demonstrated comparable
clinical activity to cetuximab in a proof-of-concept study
in the second-line treatment of R/M HNSCC [48,49], as
well as antitumour activity in preclinical models [46,47].
Afatinib has also shown promising clinical efficacy in
NSCLC and it is expected that activity of this nature will
be mirrored in the treatment of R/M HNSCC.
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